Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte, Inc.

Humacyte ($HUMA) announced an update on their ongoing clinical study. Humacyte, Inc. is launching a Phase 4 multicenter study called “A Phase 4 Obs...

Humacyte’s Symvess Trauma Study: Real-World Data Push With Investor Upside

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Annexon Biosciences (ANNX), Humacyte (HUMA) and TSca...

Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Humacyte (HUMA) and TScan Therapeutics (TCRX)

The latest announcement is out from Humacyte ( ($HUMA) ). On July 31, 2026, Humacyte disclosed that Nasdaq notified the company its common stock ha...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HUMA	$0.60	0.00%	32.78M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HUMA	$0.60	0%	32.78M
3
4
5
6

HUMA

Get Humacyte, Inc. Data in Excel

Get Humacyte, Inc. Data in Excel